FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer

Article

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer (TNBC) who are eligible for treatment with atezolizumab (Tecentriq) plus chemotherapy, according to Roche, the assay’s manufacturer.

The drug regimen also just received FDA approval as the first cancer immunotherapy regimen approved for breast cancer.

The VENTANA PD-L1 (SP142) Assay was developed to enhance visual contrast of tumor-infiltrating immune cell staining — which is expressed on tumor-infiltrating immune cells rather than on tumor cells themselves in TNBC. For example, the 3 most common proteins associated with breast cancer growth – estrogen receptor, progesterone receptor and HER2 – are not expressed on the tumor in this disease.

“Triple-negative breast cancer is an aggressive disease that, until now, has had limited treatment options,” Michael Heuer, CEO of Roche Diagnostics, said in a press release. “This assay plays a pivotal role in helping physicians identify patients that can benefit from Tecentriq therapy, providing better patient care. At Roche, we build on our capacity to research both targeted medicines and companion diagnostics under one roof, so we can provide the right treatment to the right patient at the right time.”

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Photo of a woman with brown hair and bangs, surrounded by a blue border
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Related Content